openPR Logo
Press release

Nonalcoholic Steatohepatitis Therapeutics Market Predicted to Rake in US$ 20.27 bn by 2025

01-16-2018 07:34 AM CET | Health & Medicine

Press release from: TMR - Research Report

/ PR Agency: TMR - Research Report
Nonalcoholic Steatohepatitis Therapeutics Market Predicted

The global nonalcoholic steatohepatitis therapeutics market is dominated by companies such as Intercept Pharmaceuticals Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Zydus Cadila, AstraZeneca plc., Gilead Sciences, Inc., and Immuron Ltd. Key companies are focusing on the introduction of new drugs and therapeutics to treat nonalcoholic steatohepatitis (NASH). As per the Natural Medical Journal, the occurrence of nonalcoholic fatty liver diseases is expected to increase in the U.S., which is likely to propel the global market in the years to come. This is anticipated to benefit the global nonalcoholic steatohepatitis therapeutics market in many ways. Transparency Market Research (TMR), in its new report, states that key companies are targeting to enhance the healthcare infrastructure and invest more on research and development activities to discover a new drug to treat nonalcoholic fatty liver diseases.

Read Report Overview: http://www.transparencymarketresearch.com/nonalcoholic-steatohepatitis-market.html

“The prevalence of NASH in people with severe obesity is expected to be the highest,” states a TMR analyst. The global nonalcoholic steatohepatitis therapeutics market is expected to reach US$20.27 bn by 2025. Based on drug type, the global nonalcoholic steatohepatitis therapeutics market is expected to be led by elafibranor segment. The elafibranor segment is predicted to reach US$10,121.94 mn by 2025. The many benefits of elafibranor to treat NASH have made this drug type popular than others. Key companies are taking efforts to invest more into research and development activities to enhance this drug class, which is expected to propel this segment. This pipeline drug type is expected to have better prospects in the future as there are not many treatments available to treat NASH, says a TMR analysts. The rising occurrence of NASH is expected to benefit this drug type in the near future.

Key companies operating in the global nonalcoholic steatohepatitis therapeutics market are likely to increase their research and development activities to introduce new technologies to manufacture new drugs to treat NASH. The introduction of new innovative effective, and safe drugs is expected to propel the global nonalcoholic steatohepatitis therapeutics market. Manufacturers are focusing on changing government rules and drug approval procedures before introducing new drugs in the global market. Stringent government rules are expected to restrict the introduction of new drugs, which is a key challenge for the manufacturers.

Request a sample of report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691

Rising obesity to strengthen global market

Nonalcoholic steatohepatitis commonly affects people with diabetes or obese people. The rising number of people with diabetes is expected to drive the demand for NASH therapeutics. The increasing pool of obese people is another factor expected to contribute towards the growth of the global nonalcoholic steatohepatitis therapeutics market. The developments in the healthcare infrastructure and therapeutic strategies are predicted to benefit the global nonalcoholic steatohepatitis therapeutics market.

Weak pipeline continues to hamper global market

A weak product pipeline is expected to hamper the growth of the global nonalcoholic steatohepatitis therapeutics market. There are not many therapies and drugs to treat NASH, which is a challenge for the leading players operating in this global market.

Buy Nonalcoholic Steatohepatitis Therapeutics Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=7691<ype=S

Developing nations to offer new opportunities

Key companies are likely to target the developing nations to capture a significant share of the untapped market. Many emerging nations are offering growth opportunities to the leading manufacturers of nonalcoholic steatohepatitis therapeutics. The entry of new companies is also predicted to benefit the global market for nonalcoholic steatohepatitis therapeutics. However, with the entry of new companies, the global market is expected to be highly competitive in nature.

This information is based on the findings of a report published by Transparency Market Research titled “Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015-2025.”
The nonalcoholic steatohepatitis therapeutics market is segmented as follows:

Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market, By Drug Type

Overview
Potential Drug Candidates in Phase III
Obeticholic Acid (OCA)
Aramchol (arachidyl amido cholanoic acid)
Saroglitazar
Elafibranor

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nonalcoholic Steatohepatitis Therapeutics Market Predicted to Rake in US$ 20.27 bn by 2025 here

News-ID: 901066 • Views:

More Releases from TMR - Research Report

Global Tissue Extraction System Market: Trends and Opportunities 2017 - 2025
Global Tissue Extraction System Market: Trends and Opportunities 2017 - 2025
Global Tissue Extraction System Market: Overview The global tissue extraction system market is foretold to display an impressive growth rate in the coming years. This could be owing to the need for tissue extraction or biopsy for cancer analysis after the patient has been suspected of carrying the disease. The procedure is extremely vital for diagnosing the disease. Thus, increasing prevalence of carcinogenic agents, compromised immunity levels, and rising incidence of
Neurology Sterile Injectable Market: Growth Factors, Applications, Regional Analysis 2017 - 2025
Neurology Sterile Injectable Market: Growth Factors, Applications, Regional Anal …
Neurology sterile injectables are generally administered to individuals suffering from pain linked to the nerves. Neuropathic pain injections are used to provide relief to these individuals. Neurology sterile injectable block the pain signal from reaching the brain. Neurological sterile injection can be administered at sympathetic nervous system, trigger points, dorsal roots, and peripheral nerves. The most commonly use neurological injectable used for nerve block are steroid injection, opioids, and local
External Fixator Devices Market: Global Survey and Trend Research
External Fixator Devices Market: Global Survey and Trend Research
External fixator devices are used to stabilize and support long bone open fractures to help the patient carry body’s weight as well as movement. Schanz screws, connecting rods, and clamps are used in case of unipolar external fixators. Circulatory fixators include circular rings, wires, connecting rods, and struts. The external fixator devices provide rigid fixation along with fixed distraction of the fracture fragments. The major advantage of external fixator devices
Anorectal Preparations Market Trends, and Forecast 2017 - 2025
Anorectal Preparations Market Trends, and Forecast 2017 - 2025
Anorectal preparations are products that contain a combination of an anti-inflammatory agent, or a pain reliever, and a local anesthetic as a suppository, or an ointment. External or internal hemorrhoids are treated by the topical application of anorectal preparations. Hemorrhoids are masses or lumps of tissue in the anus that contain enlarged blood vessels. The formation of hemorrhoids is due to an increase in abdominal pressure. Frequent constipation, which is

All 5 Releases


More Releases for NASH

The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date. The NASH
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028 The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining
NASH Market Insight and Landscape report
Report Snapshot: NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their
04-07-2017 | Arts & Culture
Memphia PR
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017. Listening to the Beatles and Jack White growing
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will